Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Lille
With
GlaxoSmithKline
it will assess the activation state of blood eosinophils in SSc patients compared to healthy controls (ECP production in vitro, surface activation markers, whole transcriptome array, ..).
it will also study skin eosinophils and their recruitment (extracellular eosinophil granules, eotaxins production in skin, ..)
Age
18–66
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
For SSc patients:
Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20)
Having signed the informed consent
Eosinophils ≥ 0.1 G / L on the last blood test (\<3 months)
For healthy subjects:
Without chronic pathology requiring long-term treatment
Eosinophils between 0.1 and 0.4 G / L on recent blood test (\<3 months)
You may not be if
Patient with an infection, state of emergency or progressive neoplastic pathology
Pregnant or lactating women
History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic conjunctivitis)
Allergy to local anesthetics (for scleroderma patients only)
Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory effects of scleroderma, only patients with at least 10 g of hemoglobin will be included